Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update

Sanofi SA (SNY) announced an update on their ongoing clinical study.

Sanofi (SNY) is running a Phase 1 basket study called “A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Select Autoimmune Rheumatic Diseases.” The trial aims to find safe and active dose ranges for patients with lupus and rheumatoid arthritis, an area with large unmet need and sizable market potential.

The study tests SAR448501, also known as DR-0201, a lab-made antibody drug given to adults with autoimmune rheumatic diseases. It is designed to target immune cells involved in inflammation, with the goal of easing symptoms and possibly changing the course of disease if safety and activity look promising.

This is an interventional study where all patients receive the drug, but at different dose levels over time. The trial is open-label, so both doctors and patients know the treatment given, and the core aim is treatment evaluation, not comparison to placebo or standard care at this stage.

The study uses a non-randomized, sequential design in which new dose groups start only after safety checks on earlier groups. This setup lets researchers adjust and expand dosing as they learn more, speeding decisions on which doses might move into larger, later-stage trials.

The trial was first submitted on October 16, 2024, marking the formal start of the regulatory process and investor visibility. The latest update was filed on March 17, 2026, signaling that the protocol or status has been refreshed and that the trial is still active and monitored.

Each participant is followed for at least about 13 months, including screening, roughly 10 weeks of dosing, and 42 weeks of follow-up. Extra visits can continue until key blood markers recover, which underscores the focus on tracking safety signals over the long term in this early-stage program.

For investors, this update reinforces Sanofi’s push into next-generation autoimmune therapies beyond its existing immunology portfolio. Success here could support a higher long-term growth story and help Sanofi compete with players like AbbVie, Eli Lilly, and Johnson & Johnson in autoimmune disease, though near-term revenue impact is still years away.

Early-stage, open-label data tend to sway sentiment more than fundamentals, so future safety or activity readouts could add volatility to SNY shares. The ongoing status and recent update suggest steady progress, and the study remains active with more details available on the ClinicalTrials portal.

To learn more about SNY’s potential, visit the Sanofi SA drug pipeline page.